LINC01341: A Potential Drug Target Or Biomarker (G149134)

Target Name: LINC01341

NCBI ID: G149134

LINC01341

Other Name(s): Long intergenic non-protein coding RNA 1341 | long intergenic non-protein coding RNA 1341

LINC01341: A Potential Drug Target Or Biomarker

LINC01341 is a non-protein coding RNA (ncRNA) molecule that has been identified by bioinformatic analysis as belonging to the LINC RNA family. This family ofncRNAs has been identified in a variety of organisms, including humans, and is characterized by the presence of a specific open reading frame (ORF) that is usually conserved across different organisms.

One of the key features of LINC01341 is its length. It has a length of 292 nucleotides, which is relatively long for an RNA molecule. However, its length is not the only feature that makes it interesting.

The LINC01341 gene is located on chromosome 6 (chromosome 6 is also known as X chromosome) and it is expressed in various tissues and organs, including brain, heart, muscle, and liver. It is also highly expressed in the tests and has been shown to be involved in the development and maintenance of tissues.

Another feature that makes LINC01341 interesting is its expression pattern. It is generally expressed in a cell type with lower expression levels, and its expression is highly dependent on the cell type and the specific conditions in which the cell is treated. This allows it to be used as a potential drug target or biomarker, as changes in the expression of LINC01341 could be associated with the development of certain diseases.

One of the potential reasons why LINC01341 is a drug target is its involvement in several diseases, including cancer. Several studies have shown that LINC01341 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, it has been shown to be involved in the regulation of cell proliferation, which is a key factor in the development of many diseases.

Another potential reason why LINC01341 is a drug target is its involvement in autoimmune diseases. Several studies have shown that LINC01341 is highly expressed in various autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. Additionally, it has been shown to be involved in the regulation of immune cells, which is a key factor in the development of many autoimmune diseases.

Another potential reason why LINC01341 is a drug target is its involvement in neurodegenerative diseases. Several studies have shown that LINC01341 is highly expressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, it has been shown to be involved in the regulation of neurotransmitter synthesis and release, which is a key factor in the development of many neurodegenerative diseases.

In addition to its potential as a drug target, LINC01341 also has potential as a biomarker. Its expression is highly dependent on the specific conditions in which the cell is treated, which makes it a potential indicator of disease status. Additionally, its length and conservation across different organisms make it a potential representative of a specific gene family, which could be useful for identifying potential drug targets or biomarkers.

Overall, LINC01341 is a non-protein coding RNA molecule that has a number of interesting features that make it potential as a drug target or biomarker. Its length, its expression pattern, and its involvement in several diseases, including cancer, autoimmune diseases, and neurodegenerative diseases, make it an attractive candidate for further study. Further research is needed to fully understand the potential of LINC01341 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1341

The "LINC01341 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01341 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets